SCHEMBL30613622

SCHEMBL30613622

CC(C)n1ccc(-c2cc3ncccc3c(OC[C@@H]3CNCCO3)n2)c1

nearest known ligand 0.46

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 19/20 0.46
▸ IRAK4 Q9NWZ3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31676417 0.96 SYK (0.46) SYK
SCHEMBL30613709 0.90 SYK (0.49) SYK
SCHEMBL31676300 0.87 SYK (0.49) SYK
SCHEMBL31676357 0.86 SYK (0.46) SYK
SCHEMBL31676415 0.86 SYK (0.46) SYKIRAK4
SCHEMBL31676118 0.85 SYK (0.48) SYK
SCHEMBL31676085 0.85 SYK (0.48) SYK
SCHEMBL31676131 0.85 SYK (0.43) SYK
SCHEMBL30613650 0.85 SYK (0.45) SYK
SCHEMBL26134875 0.85 SYK (0.45) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263408-A1 SPLEEN TYROSINE KINASE INHIBITORS UNIQUEST PTY LTD (AU) 2025-08-21 — — US disclosed
EP-4504724-A1 SPLEEN TYROSINE KINASE INHIBITORS Uniquest Pty Limited (AU) 2025-02-12 — — EP disclosed
CN-119325474-A Spleen tyrosine kinase inhibitors 尤尼奎斯特公司 2025-01-17 — — CN disclosed
WO-2023193054-A1 SPLEEN TYROSINE KINASE INHIBITORS UNIQUEST PTY LTD (AU) 2023-10-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263408-A1 SPLEEN TYROSINE KINASE INHIBITORS LCK, BTK, SYK SYK 3/4885IRAK4 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback